Market Research Industry Reports

Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The companys Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Equity Offering 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 14
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 18
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 19
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 21
Sunesis Pharma Prices Public offering of Shares for USD8 Million 23
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 24
Asset Transactions 25
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 25
Sunesis Pharmaceuticals Inc - Key Competitors 27
Sunesis Pharmaceuticals Inc - Key Employees 28
Sunesis Pharmaceuticals Inc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 30
Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 32
Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 34
May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 36
Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 38
Corporate Communications 40
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 40
Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 41
Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 42
Product News 43
12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 43
07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 44
Product Approvals 45
May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 45
Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 46
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 47
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 48
Clinical Trials 49
Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List Of Tables

List of Tables
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 14
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 18
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 19
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 21
Sunesis Pharma Prices Public offering of Shares for USD8 Million 23
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 24
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 25
Sunesis Pharmaceuticals Inc, Key Competitors 27
Sunesis Pharmaceuticals Inc, Key Employees 28
Sunesis Pharmaceuticals Inc, Subsidiaries 29

List Of Figures

List of Figures
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The companys Vosaroxin is being developed in Phase III

USD 250View Report

Sunesis Pharmaceuticals, Inc. - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Sunesis Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Sunesis Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350View Report

Alexza Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Alexza Pharmaceuticals Inc (Alexza), a wholly owned subsidiary of Ferrer Therapeutics Inc, focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :50
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube